Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Completed Not applicable Interventional

Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion

NCT04679896
View directory record Official record
Conditions
Degenerative Disc Disease, Spine Fusion
Interventions
MagnetOs Putty
Device
Lead sponsor
Kuros Biosurgery AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints

NCT01604070
View directory record Official record
Conditions
Foot Diseases
Interventions
Not listed
Lead sponsor
eMedtrain Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Cambridge, Massachusetts • Vineland, New Jersey • Alexandria, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 22, 2026, 4:57 AM EDT
Not listed No phase listed Observational

Clinical and Radiographic Outcomes of TLIF w/3D Printed Cellular Implant

NCT05023733
View directory record Official record
Conditions
Foraminal Stenosis, Degenerative Disc Disease, Lumbar Spondylolisthesis, Lumbar Spinal Stenosis
Interventions
CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®
Device
Lead sponsor
Farhan Karim
Other
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 2 Interventional

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Interventions
TAS-120
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
La Jolla, California • Tampa, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

NCT04552704
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm
Interventions
CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration
Biological · Drug
Lead sponsor
Tianhong Li
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Early Postoperative Home Exercise Program After Cervical Spine Surgery

NCT02720172
View directory record Official record
Conditions
Spinal Fusion, Cervical Spine Degenerative Disease
Interventions
Early Home Exercise Program, Usual Care
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

Thromboelastography-Guided Fluid Management in Spinal Surgery

NCT03999086
View directory record Official record
Conditions
Spinal Fusion
Interventions
Intervention, Control Group
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Withdrawn No phase listed Observational

ConfirmMDx Assay in Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy

NCT03597386
View directory record Official record
Conditions
Prostate Disease
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion

NCT03104816
View directory record Official record
Conditions
Fusion of Spine, Lumbar Region
Interventions
Acetaminophen IV Soln 10 MG/ML, Acetaminophen, Hydromorphone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

NCT05470400
View directory record Official record
Conditions
HIV
Interventions
FP conjugate vaccine (25 mcg), FP conjugate vaccine (200 mcg), Trimer 6931 (100 mcg), Trimer 6931 (200 mcg), Trimer 4571 (200 mcg), Trimer 4571 (100 mcg)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT06915753
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, Locally Advanced Unresectable Hepatocellular Carcinoma
Interventions
TYRA-430
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Early Phase 1 Interventional

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

NCT07261657
View directory record Official record
Conditions
Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
Interventions
Biospecimen Collection, Computed Tomography, Leukapheresis, Magnetic Resonance Imaging, Nogapendekin Alfa Inbakicept, X-Ray Imaging
Procedure · Biological
Lead sponsor
Seth Pollack
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Study of an Expandable Interbody Device for the Lumbar Spine

NCT02075554
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
CALIBER
Device
Lead sponsor
Globus Medical Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Miami Beach, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Enrolling by invitation No phase listed Observational

Virtuos Bone Graft in Lumbar Fusion

NCT06686017
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Not listed
Lead sponsor
Orthofix Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
South Bend, Indiana • Southfield, Michigan • Missoula, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

NCT05267106
View directory record Official record
Conditions
Glioblastoma, Adult-type Diffuse Gliomas
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
32
States / cities
Beverly Hills, California • Duarte, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 4 Interventional

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

NCT07174349
View directory record Official record
Conditions
Urinary Retention Postoperative
Interventions
Uroselective alpha-1-adrenergic receptor antagonist, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational Results available

Understanding Non-Response in Spine Fusion Surgery

NCT02611479
View directory record Official record
Conditions
Spine Fusion
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Seattle, Washington • Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Interventions
Oral repotrectinib (TPX-0005)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
Up to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants

NCT03859323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SHP681, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Ketorolac vs Oxycodone for Great Toe Arthrodesis

NCT05054868
View directory record Official record
Conditions
Arthrodesis
Interventions
Oxycodone, Ketorolac
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit

NCT04720235
View directory record Official record
Conditions
Covid19, Corona Virus Infection
Interventions
Lucira COVID-19 All-In-One test kit
Device
Lead sponsor
Lucira Health Inc
Industry
Eligibility
14 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Changes in Microbial Status From Dentate, Edentulous and After Dental Implant Placement

NCT06149585
View directory record Official record
Conditions
Edentulous Mouth, Periodontal Diseases, Periodontitis, Adult, Microbial Colonization
Interventions
Microbial Sampling
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura

NCT00002250
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura ( ITP ), HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:57 AM EDT